{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:34:16Z","timestamp":1793230456002,"version":"4.5.0"},"reference-count":27,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2024 headache research grant from the Korean Headache Society"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are a breakthrough migraine treatment, but long-term compliance under limited public insurance coverage has not been well known. This study explores one-year treatment patterns and outcomes of CGRP mAbs using real-world data. Methods: This multicenter retrospective study included migraine patients treated with CGRP monoclonal antibodies (CGRP mAbs) from July 2022 to June 2023. Treatment discontinuation was defined as a gap of over 60 days between injections. Among patients with 12 months of follow-up, adherence was measured using the Proportion of Days Covered (PDC), calculated as the ratio of days covered to the follow-up duration, with PDC \u2265 80% indicating good adherence. Efficacy was also assessed, defined as a \u226550% reduction in monthly headache days and acute medication use. Results: The study included 140 patients (mean age 44.6 \u00b1 12.1 years; 82.9% female). Migraine without aura was predominant (93.6%), and 65.0% had chronic migraine. CGRP mAbs discontinuation occurred in 71.4% of patients, primarily due to headache improvement (22.9%) or lack of efficacy (15.0%). Among 81 patients with 12 months of follow-up, good adherence was observed in 40.7% of patients. Among these patients, 60.6% achieved a \u226550% reduction in monthly headache days, and 51.9% showed a \u226550% reduction in monthly acute medication use. Conclusions: More than two-thirds of patients discontinued the CGRP mAb within 1 year, so these findings emphasize the need for strategies to improve adherence and optimize follow-up plans to enhance patient support.<\/jats:p>","DOI":"10.3390\/jcm14030734","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:49:54Z","timestamp":1737611394000},"page":"734","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["One-Year Compliance After Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy for Migraine Patients in a Real-World Setting: A Multicenter Cross-Sectional Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Mi-kyoung","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Neurology, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, Hwaseong 18450, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-9222","authenticated-orcid":false,"given":"Jong-Hee","family":"Sohn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon 200704, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung-Jin","family":"Cha","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Police Hospital, Seoul 05715, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9532-5769","authenticated-orcid":false,"given":"Yoo Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14068, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-2831","authenticated-orcid":false,"given":"Yooha","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, Hwaseong 18450, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-6521","authenticated-orcid":false,"given":"Hee-Jin","family":"Im","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, Hwaseong 18450, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4053-3763","authenticated-orcid":false,"given":"Soo-Jin","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, Hwaseong 18450, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global Epidemiology of Migraine and Its Implications for Public Health and Health Policy","volume":"19","author":"Steiner","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the Target of New Migraine Therapies\u2014Successful Translation from Bench to Clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/jnnp-2020-324674","article-title":"Calcitonin Gene Related Peptide in Migraine: Current Therapeutics, Future Implications and Potential Off-Target Effects","volume":"92","author":"Ray","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.17340\/jkna.2020.2.2","article-title":"Calcitonin Gene-Related Peptide Targeting Therapies for Migraine: A New Era for Migraine Treatment","volume":"38","author":"Park","year":"2020","journal-title":"J. Korean Neurol. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3988\/jcn.2023.0311","article-title":"Treatment Outcome after Switching from Galcanezumab to Fremanezumab in Patients with Migraine","volume":"20","author":"Youn","year":"2024","journal-title":"J. Clin. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin Gene-Related Peptide-Targeting Therapies Are a First-Line Option for the Prevention of Migraine: An American Headache Society Position Statement Update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache J. Head Face Pain"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation Guideline on the Use of Monoclonal Antibodies Targeting the Calcitonin Gene Related Peptide Pathway for Migraine Prevention\u20132022 Update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kim, B.S., Chung, P.W., Chung, J.M., Park, K.Y., Moon, H.S., Park, H.K., Bae, D.W., Seo, J.G., Sohn, J.H., and Song, T.J. (2025). Evidence-Based Recommendations on Pharmacologic Treatment for Migraine Prevention: A Clinical Practice Guideline from the Korean Headache Society. Headache Pain Res.","DOI":"10.62087\/hpr.2024.0019"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","article-title":"Long-Term Effectiveness of Three Anti-Cgrp Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the Midas Score","volume":"36","author":"Iannone","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0333102417741297","article-title":"Cgrp, a Target for Preventive Therapy in Migraine and Cluster Headache: Systematic Review of Clinical Data","volume":"39","author":"Khan","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3331024221137091","DOI":"10.1177\/03331024221137091","article-title":"Open-Label Trials for Cgrp-Targeted Drugs in Migraine Prevention: A Narrative Review","volume":"43","author":"Raffaelli","year":"2023","journal-title":"Cephalalgia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1474-4422(18)30085-1","article-title":"International Classification of Headache Disorders","volume":"17","author":"Olesen","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.jval.2024.04.002","article-title":"Utilization, Expenditure, and Treatment Patterns Associated with Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland","volume":"27","author":"Smith","year":"2024","journal-title":"Value Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5124\/jkma.2021.64.2.130","article-title":"Evaluation and Improvement of Adherence to Medication","volume":"64","author":"Lee","year":"2021","journal-title":"J. Korean Med. Assoc. Taehan Uisa Hyophoe Chi"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40545-021-00385-w","article-title":"Estimating Proportion of Days Covered (Pdc) Using Real-World Online Medicine Suppliers\u2019 Datasets","volume":"14","author":"Mulick","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/PPA.S346660","article-title":"Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab Versus Conventional Preventive Treatments for Migraine: A Retrospective Us Claims Study","volume":"16","author":"Varnado","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"ref_17","first-page":"1119","article-title":"Real-World Persistence and Costs among Patients with Chronic Migraine Treated with Onabotulinumtoxina or Calcitonin Gene-Related Peptide Monoclonal Antibodies","volume":"29","author":"Schwedt","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/head.14218","article-title":"Real-World Persistence of Erenumab for Preventive Treatment of Chronic and Episodic Migraine: Retrospective Real-World Study","volume":"62","author":"Gladstone","year":"2022","journal-title":"Headache"},{"key":"ref_19","first-page":"24","article-title":"Persistence, Effectiveness, and Tolerability of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Patients with Chronic Migraine","volume":"65","author":"Ojeda","year":"2024","journal-title":"Headache"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1212\/WNL.0000000000203466","article-title":"Adherence and Persistence of Calcitonin Gene-Related Peptide Monoclonal Antibodies in Patients with Migraine: A Real-World Study (P12-12.007)","volume":"100","author":"Varnado","year":"2023","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","article-title":"Cgrp Monoclonal Antibodies in Migraine: An Efficacy and Tolerability Comparison with Standard Prophylactic Drugs","volume":"22","author":"Vandervorst","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1007\/s10072-022-06199-1","article-title":"The Ultimate Guide to the Anti-Cgrp Monoclonal Antibodies Galaxy","volume":"43","author":"Mascarella","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s10194-024-01850-y","article-title":"Genetic Variants Associated with Response to Anti-Cgrp Monoclonal Antibody Therapy in a Chronic Migraine Han Chinese Population","volume":"25","author":"An","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/head.14053","article-title":"Understanding the Migraine Treatment Landscape Prior to the Introduction of Calcitonin Gene-Related Peptide Inhibitors: Results from the Assessment of Tolerability and Effectiveness in Migraine Patients Using Preventive Treatment (Attain) Study","volume":"61","author":"Kawata","year":"2021","journal-title":"Headache"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pavelic, A.R., Wober, C., Riederer, F., and Zebenholzer, K. (2022). Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data. Cells, 12.","DOI":"10.20944\/preprints202211.0177.v1"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mavridis, T., Deligianni, C.I., Karagiorgis, G., Daponte, A., Breza, M., and Mitsikostas, D.D. (2021). Monoclonal Antibodies Targeting Cgrp: From Clinical Studies to Real-World Evidence-What Do We Know So Far?. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070700"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11940-017-0463-4","article-title":"Anti-Cgrp Monoclonal Antibodies: The Next Era of Migraine Prevention?","volume":"19","author":"Tso","year":"2017","journal-title":"Curr. Treat. Options Neurol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/734\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:34:32Z","timestamp":1759919672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030734"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030734","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}